On August 28, 2026, the FDA approved Moderna's mNEXSPIKE vaccine and gave the green light to Novavax's Nuvaxovid vaccine. Separately, ProFound Therapeutics was formed by Flagship Pioneering.
1 report, 1 independent
Updated Aug 28
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
On August 28, 2026, the FDA approved Moderna's mNEXSPIKE vaccine and gave the green light to Novavax's Nuvaxovid vaccine. Separately, ProFound Therapeutics was formed by Flagship Pioneering.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
- FDA
-
Moderna
American biotechnology company
-
Novavax
company in Gaithersburg, Maryland
Nothing else this week.
Related events
- Trump administration pushes vaccine approval while FDA moves forward with Moderna vaccine, with Fauci noting incomplete protection.
- Moderna and Merck announced a partnership on their mRNA cancer vaccine trial, leading to analyst rating hikes.
- Moderna announced a collaboration with Merck KGaA regarding a personalized cancer vaccine platform.
- Moderna combined its vaccine with Merck's Keytruda drug.
- Analyst comments on industry trends regarding Moderna's competition in the cancer vaccine market.